August 22, 2025

New CT Score Tracks Pneumonia Stage Progression

Researchers validate a visual CT scoring system designed to improve classification of pneumonia-related lung changes in clinical and research settings.

Conexiant

August 22, 2025

Seven-Factor Tool Improves Sepsis Death Prediction

An admission-based model predicted 28-day mortality more accurately than SOFA and APACHE II, offering a potential tool for early risk stratification in ICU patients with sepsis secondary to pneumonia.

Conexiant

August 22, 2025

Linear Hyperpigmentation After Chemotherapy: What's Your Diagnosis?

A 15-year-old girl developed distinctive, painless, whip-like streaks across her trunk and back after receiving combination chemotherapy for ovarian yolk sac tumor. What’s your diagnosis?

Conexiant

August 20, 2025

Frailty Risk High in PRISm Patients

Frailty screening emerges as a critical consideration in PRISm patients as new findings reveal overlapping systemic vulnerabilities with COPD, despite preserved lung function ratio.

Conexiant

August 19, 2025

AAP Vaccine Recommendations Veer From ACIP

AAP released 2025 evidence-based US childhood and adolescent immunization schedule with updates for RSV, influenza, COVID-19, HPV, and meningococcal vaccines.

Conexiant

August 18, 2025

Early Risdiplam Use in Presymptomatic SMA Infants

Presymptomatic treatment with risdiplam was associated with improved motor development and survival without permanent ventilation in infants with spinal muscular atrophy (SMA), according to 24-month results from the phase 2 RAINBOWFISH trial published in the New England Journal of Medicine.

Conexiant

August 15, 2025

Approved: HPV-Targeted Immunotherapy for Recurrent Respiratory Papillomatosis

Standard management has relied on repeated surgical debulking, which does not eradicate underlying HPV infection.

Conexiant

August 15, 2025

COVID-19 Booster in Pregnancy Linked to Higher Infant Antibodies

A COVID-19 mRNA booster given during pregnancy is associated with greater transplacental antibody transfer and sustained infant antibody levels through 6 months of age.

Conexiant

August 12, 2025

FDA Approves First Therapy for Non-cystic Fibrosis Bronchiectasis

Brensocatib (Brinsupri) will offer a new treatment option for patients 12 years and older.

Conexiant